| Identification | Back Directory | [Name]
LGD-6972 | [CAS]
1207989-09-0 | [Synonyms]
LGD-6972
LGD6972; LGD 6972
Ethanesulfonic acid, 2-[[4-[(2R)-2-[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl]-3-oxo-3-[(2',4',6'-trimethyl[1,1'-biphenyl]-4-yl)amino]propyl]benzoyl]amino]- | [Molecular Formula]
C43H46N2O5S | [MDL Number]
MFCD28411370 | [MOL File]
1207989-09-0.mol | [Molecular Weight]
702.9 |
| Chemical Properties | Back Directory | [density ]
1.206±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:125.0(Max Conc. mg/mL);177.83(Max Conc. mM) | [form ]
Solid | [pka]
1.36±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research[1]. | [in vivo]
In vivo, LGD-6972 reduces acute glucagon-stimulated hyperglycaemia as well as the hyperglycaemia observed in diabetic mouse models. The pharmacological activity of LGD-6972 appears to be mediated primarily by inhibiting glucagon receptor signaling[1]. | [References]
[1] Vajda EG, et al. Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2017 Jan;19(1):24-32. DOI:10.1111/dom.12752 |
|
|